+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Label-Free Detection - Global Market Trajectory & Analytics

  • ID: 4805646
  • Report
  • April 2021
  • Region: Global
  • 384 pages
  • Global Industry Analysts, Inc
The global Label-Free Detection market is projected to reach US$1.3 billion by 2025, driven by growing drug R&D, rising competitive pressure to reduce cost of drug development and the resulting need for cost-effective and efficient screening technologies. Traditional label-based assays are beset with drawbacks such as high cost associated with label preparation; lower levels of sensitivity and accuracy as measurements are made indirectly using a labeled reactant; risk of certain antigen/antibody reactions not being detected; requires multiple steps and is time consuming; and tendency to modify the physicochemical or binding properties making accurate drug characterization difficult. In this regard, label-free assays for biochemical and cell-based drug discovery is growing in importance due to the many benefits offered such as ability to identify difficult target classes, better insights offered into drug binding kinetics and drug residence time; highly sensitive detection of small molecules, proteins and cells; simple assay procedure; less potential for false positive/negatives; eliminates labelling & reagent costs; aids in high-throughput, independent screening of whole cells; provides new insights into compound action and helps devise better optimization strategies; increased sensitivity and specificity; more accurate quantification of biological responses, among others. All of these benefits are helping replace traditional techniques like radioactive assays, enzyme-labelled assays (ELISA assays), fluorescent labeled assays, luminescent labeled assays, and Chemiluminescence immunoassay (CLIA) with label-free options.

Few of the major trends influencing growth in the market include growing population, rising disease burden and the need for new generation drugs and therapies; growing pressure on pharmaceutical companies to strengthen their drug pipelines against the backdrop of patent expiry, competition from generics and reduction in profits/revenues; increased government investment support for life sciences research to develop effective, safe and affordable drugs; growing interest in genomics research and proteomics; growing production of recombinant therapeutic proteins; expanding pharmaceutical contract research outsourcing and new opportunities in Asia-Pacific; growing market for biosimilars and increased need for label-free detection as an analytical tool to demonstrate biosimilarity; rising incidence of food allergy and the ensuing demand for label-free detection of allergens in food; and strong opportunity for label free detection in cancer diagnosis and characterization. The United States and Europe represent large markets worldwide with a combined share of 64.8%. China ranks as the fastest growing market with a 9.7% CAGR over the analysis period supported by the globalization of the countrys life sciences sector. The Chinese governments dedicated support of the industry has resulted in China developing innovative drug molecules for the domestic healthcare market. The country also plans to export Chinese-made pharmaceuticals. The recent approval of countrys first WHO-prequalified vaccine brightens the outlook for Chinese-made pharmaceuticals. The expected growth of the countrys life sciences sector and pharmaceutical R&D spending which is poised to reach over US$30 billion by 2020, bodes well for the adoption and growth of label-free detection. Asia-Pacific excluding China follows next with a 9.5% CAGR led by India, and other Southeast Asian countries.

Select Competitors (Total 41 Featured):
  • Agilent Technologies, Inc.
  • AMETEK, Inc.
  • Attana AB
  • Corning Inc.
  • Hitachi High-Technologies Corp.
  • Horiba Ltd.
  • Malvern Panalytical Ltd.
  • PerkinElmer, Inc.
  • Thermo Fisher Scientific, Inc.
  • Danaher Corporation
  • Molecular Devices, LLC
  • AB SCIEX
  • GE Healthcare Life Sciences
  • TA Instruments
  • Merck KGaA.
Note: Product cover images may vary from those shown
I. METHODOLOGY

II. EXECUTIVE SUMMARY
  • Influencer Market Insights
  • World Market Trajectories
  • Growing Population, Rising Disease Burden, the Need for New Generation Drugs & Rising Pharma R&D, the Cornerstone for Growth in the Market
  • Exhibit 1: Rising Prevalence of Chronic Diseases Amplifies the Need for Advancing Healthcare Research: Global Cost of Chronic Diseases (In US$ Billion) for the Years 2018 and 2030
  • Exhibit 2: Aging Population Burdens an Already Strained Healthcare System: Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • Robust Investments in Lifesciences Research to Develop Effective, Safe & Affordable Drugs Spurs Growth in the Pharmaceutical & Biotechnology Sectors
  • Better Insights Offered by Label-Free Detection into Drug Binding Kinetics & Drug Residence Time Drives Demand for this Technology in Drug Discovery: Global Pharma R&D Spending (In US$ Billion) for the Years 2017, 2019, 2022 & 2024
  • Growing Interest in Genomics Research: A Major Win for the Market
  • Exhibit 3: A Strong Vision for the Future of Genomics Creates Robust Demand for Improved Repertoire of Research Tools: Global Market for Genomics (In US$ Billion) for the Years 2019, 2022, 2024 & 2026
  • A Review of Key Market Segments
  • Impact of Covid-19 and a Looming Global Recession
  • Growing Production of Recombinant Therapeutic Proteins to Drive Gains in the Market
  • Exhibit 4: The Need to Address Unmet Medical Needs Creates New Opportunities in the Development of Therapeutic Proteins: Global Recombinant Therapeutic Antibodies & Proteins Market (In US$ Billion) for the Years 2017, 2019, 2022 and 2024
  • Expanding Pharmaceutical Contract Research Outsourcing to Drive Growth in Asia-Pacific
  • Exhibit 5: Rising Cost of Drug Safety Conformance Spurs Interest in Outsourcing Pharmacovigilance to CROs: Global Contract Research Organization Revenue (In US$ Billion) for the Years 2017, 2019, 2021 and 2023 by Geographic Region
  • Growing Market for Biosimilars Expands the Addressable Market Opportunity for Label-Free Detection as an Analytical Tool to Demonstrate Biosimilarity
  • Exhibit 6: With the Biosimilars Opportunity Ballooning to a Tempting US$4.6 Billion, Growing Research in This Space Entails Greater Use of Label-Free Techniques for Kinetic Evaluation of Monoclonal Antibodies: Global Biosimilars Market (In US$ Million) for the Years 2018, 2020 and 2022
  • Rising Incidence of Food Allergy & the Ensuing Labeling Compliance Drives Interest in Label-Free Detection of Allergens in Food
  • Exhibit 7: Growing Opportunity in Food Safety Testing Against the Backdrop of Rising Burden of Food Allergy: Global Food Safety Testing Market (In US$ Billion) for the Years 2017, 2019, 2022 and 2024
  • Strong Opportunity For Label Free Detection in Cancer Diagnosis & Characterization
  • Exhibit 8: Growing Global Burden of Cancer Throws the Spotlight on Unmet Therapy Needs: Global Cancer New Incidence & Number of Deaths (In 0000s) by Type for the Year 2018
  • Exhibit 9: Supported by the Epidemic Spread of Cancer, the Robustly Growing Cancer Diagnostics Market to Generate Revenue Opportunities for Label-Free Detection: Global Cancer Diagnostics Market (In US$ Billion) for the Years 2017, 2019 & 2022
  • Innovations in Label-Free Detection, Crucial for Long-Term Growth in the Market
  • Emerging New Applications for Label-Free Optical Biosensors Amplifies Revenue Opportunities in the Market
III. MARKET ANALYSIS

IV. COMPETITION
  • Total Companies Profiled: 41
Note: Product cover images may vary from those shown
Adroll
adroll